July 24, 2017 05:47 PM EDT
R&D
Pharma

No­vavax makes a case for a do-over on its failed RSV vac­cine — but it's an up­hill climb

John Carroll

Editor & Founder

Ten months af­ter No­vavax shares $NVAX were rout­ed by the fail­ure of its RSV F vac­cine in Phase III in old­er sub­jects, the biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

Ge­of­frey Porges ex­its Schrödinger with CFO swap; A new board seat for As­traZeneca's Pas­cal So­ri­ot

Merus’ Phase 2 over­all sur­vival da­ta reach ‘home run’ sce­nario — an­a­lyst

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times